Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction

The value of thrombolytic therapy for patients with acute myocardial infarction has been firmly established. To identify the thrombolytic approach that most effectively produces sustained patency of the infarct-related artery and improves survival, the Global Utilization of Streptokinase and Tissue...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 1995-05, Vol.332 (21), p.1418-1424
Hauptverfasser: Mark, Daniel B, Hlatky, Mark A, Califf, Robert M, Naylor, C. David, Lee, Kerry L, Armstrong, Paul W, Barbash, Gabriel, White, Harvey, Simoons, Maarten L, Nelson, Charlotte L, Clapp-Channing, Nancy, Knight, J. David, Harrell, Frank E, Simes, John, Topol, Eric J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The value of thrombolytic therapy for patients with acute myocardial infarction has been firmly established. To identify the thrombolytic approach that most effectively produces sustained patency of the infarct-related artery and improves survival, the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) investigators compared four different regimens: accelerated tissue plasminogen activator (t-PA), streptokinase with intravenous heparin, streptokinase with subcutaneous heparin, and a combination of t-PA and streptokinase. 1 (“Accelerated” refers to the administration of t-PA over a period of 11/2 hours — with two thirds of the dose given in the first 30 minutes — rather . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJM199505253322106